Israel’s Pluristem (reported here previously) has launched an FDA-cleared Covid-19 expanded access program. It enables Pluristem to use its PLX-PAD cells to treat up to 100 more infected patients outside its current trials in the USA and Europe and compassionate use in Israel.

https://www.pluristem.com/wp-content/uploads/2020/08/PSTI-Expanded-Access-Program-last-version.pdf